{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T19:23:21Z","timestamp":1717701801878},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orthop\u00e4de"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1007\/s00132-007-1051-1","type":"journal-article","created":{"date-parts":[[2007,1,24]],"date-time":"2007-01-24T13:16:10Z","timestamp":1169644570000},"page":"131-135","source":"Crossref","is-referenced-by-count":1,"title":["Einsatz der Bisphosphonate in der Onkologie"],"prefix":"10.1007","volume":"36","author":[{"given":"A.A.","family":"Kurth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Diel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1051_CR1","unstructured":"Arbeitsgemeinschaft Bev\u00f6lkerungsbezogener Krebsregister in Deutschland (2006) Krebsregister. Arbeitsgemeinschaft Bev\u00f6lkerungsbezogener Krebsregister, Saarbr\u00fccken, S\u00a068"},{"key":"1051_CR2","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"Body","year":"2003","unstructured":"Body JJ, Diel IJ, Lichinitser MR et al. (2003) Intravenous Ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14: 1399\u20131405","journal-title":"Ann Oncol"},{"key":"1051_CR3","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q","volume":"88","author":"Carlin","year":"2000","unstructured":"Carlin BC, Andriole GA (2000) The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88(Suppl): 2989\u20132994","journal-title":"Cancer"},{"key":"1051_CR4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","volume":"55","author":"Coleman","year":"1987","unstructured":"Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55(1): 61\u201366","journal-title":"Br J Cancer"},{"key":"1051_CR5","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","volume":"95","author":"Dearnaley","year":"2003","unstructured":"Dearnaley DP, Sydes MR, Mason MD et al. (2003) A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PRO Trial). J Natl Cancer Inst 95: 1300\u20131311","journal-title":"J Natl Cancer Inst"},{"key":"1051_CR6","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","volume":"92","author":"Diamond","year":"2001","unstructured":"Diamond TH, Winters J, Smith A (2001) The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. Cancer 92: 1444\u20131450","journal-title":"Cancer"},{"key":"1051_CR7","unstructured":"Diel I (2003) Bisphosphonate in der Therapie des metastasierten Mammakarzinoms. J Onkol (Online-Ausgabe 04\u201303)"},{"key":"1051_CR8","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","volume":"40","author":"Diel","year":"2004","unstructured":"Diel IJ, Body JJ, Lichinitser MR et al. (2004) Improved quality of life for long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40: 1704\u20131712","journal-title":"Eur J Cancer"},{"key":"1051_CR9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1179\/joc.2005.17.5.555","volume":"17","author":"Fulfaro","year":"2005","unstructured":"Fulfaro F, Leto G, Badalamenti G et al. (2005) The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. J Chemother 17: 555\u2013559","journal-title":"J Chemother"},{"key":"1051_CR10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","volume":"5","author":"Heidenreich","year":"2002","unstructured":"Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5: 231\u2013235","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1051_CR11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00005392-200101000-00033","volume":"165","author":"Heidenreich","year":"2001","unstructured":"Heidenreich A, Hofmann R, Engelmann UH (2001) The use of bisphosphonates for the palliative treatment of painful osseous metastasis due to hormone refractory prostate cancer. J Urol 165: 136\u2013140","journal-title":"J Urol"},{"key":"1051_CR12","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","volume":"335","author":"Hortobagyi","year":"1996","unstructured":"Hortobagyi GN, Theriault RL, Porter L et al. (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335: 1785\u20131791","journal-title":"N Engl J Med"},{"key":"1051_CR13","unstructured":"Kreienberg R, Kopp I, Lorenz W et al. (2004) Interdisziplin\u00e4re Leitlinie der Deutschen Krebsgesellschaft und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften: Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau. Eine nationale S3-Leitlinie. Stand Juni 2004. Deutsche Krebsgesellschaft, Frankfurt\/M."},{"key":"1051_CR14","first-page":"2602","volume":"61","author":"Lee","year":"2001","unstructured":"Lee MV, Fong EM, Singer FR et al. (2001) Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602\u20132608","journal-title":"Cancer Res"},{"key":"1051_CR15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"Major","year":"2001","unstructured":"Major P, Lortholary A, Hon J et al. (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558\u2013567","journal-title":"J Clin Oncol"},{"key":"1051_CR16","first-page":"584","volume":"2","author":"Mundy","year":"2002","unstructured":"Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Rev 2: 584\u2013593","journal-title":"Nature Rev"},{"key":"1051_CR17","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0022-5347(05)65661-3","volume":"166","author":"Oefelein","year":"2001","unstructured":"Oefelein MG, Richuiti V, Conrad W et al. (2001) Skeletal fracture rate associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166: 1724\u20131728","journal-title":"J Urol"},{"key":"1051_CR18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","volume":"1","author":"Paget","year":"1889","unstructured":"Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 1: 571\u2013573","journal-title":"Lancet"},{"key":"1051_CR19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","volume":"11","author":"Paterson","year":"1993","unstructured":"Paterson AHG, Powles TJ, Kanis JA et al. (1993) Double-blind controlled trial of ora\u00a0l clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59\u201365","journal-title":"J Clin Oncol"},{"key":"1051_CR20","doi-asserted-by":"crossref","unstructured":"Pavlakis N, Schmidt RL, Stockler M (2005) Bisphosphonates for breast cancer (Cochrane Review). The Cochrane Database of Systematic Reviews, Issue 3, Art. No. CD003474. DOI:10.1002\/14651858.CD003474","DOI":"10.1002\/14651858.CD003474"},{"key":"1051_CR21","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","volume":"20","author":"Powles","year":"2002","unstructured":"Powles TJ, Paterson AHG, Kanis JA et al. (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20: 3219\u20133224","journal-title":"J Clin Oncol"},{"key":"1051_CR22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S8756-3282(99)00070-8","volume":"24","author":"Rogers","year":"1999","unstructured":"Rogers MJ, Frith JC, Luckman SP et al. (1999) Molecular mechanism of action of bisphosphonates. Bone 24: 73\u201379","journal-title":"Bone"},{"key":"1051_CR23","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M et al. (2003) Long-term efficacy and safety of zoledronic acid compared with pamidonate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer. Cancer 98: 1735\u20131744","journal-title":"Cancer"},{"key":"1051_CR24","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R et al. (2002) A randomised, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458\u20131468","journal-title":"J Natl Cancer Inst"},{"key":"1051_CR25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1020840311573","volume":"21","author":"Smith","year":"2002","unstructured":"Smith MR (2002) Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev 21: 159\u2013166","journal-title":"Cancer Metastasis Rev"},{"key":"1051_CR26","unstructured":"Smith MR, Shasha D, Mansour R et al. (2002) Zometa increases bone mineral density in men undergoing androgen deprivation therapy for prostate cancer. Skeletal Complications of malignancy. Third North American Symposium, Meeting Proceedings 8: 25\u201327"},{"key":"1051_CR27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdh173","volume":"15","author":"Tripathy","year":"2004","unstructured":"Tripathy D, Lichinitser M, Lazarev A et al. (2004) Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 15: 743\u2013750","journal-title":"Ann Oncol"}],"container-title":["Der Orthop\u00e4de"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00132-007-1051-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00132-007-1051-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00132-007-1051-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T12:37:21Z","timestamp":1558615041000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00132-007-1051-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["1051"],"URL":"https:\/\/doi.org\/10.1007\/s00132-007-1051-1","relation":{},"ISSN":["0085-4530","1433-0431"],"issn-type":[{"value":"0085-4530","type":"print"},{"value":"1433-0431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}